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OBJECTIVE: This study aimed to assess stathmin expression in benign and malignant phaeochromocy-
tomas and paragangliomas.
METHODS: Tissue specimens from 37 patients with malignant phaeochromocytomas (n = 5), malignant
paragangliomas (n = 3), benign phaeochromocytomas (n = 24), and benign paragangliomas (n = 5) were
analysed for stathmin expression by western blotting and immunohistochemical staining with polyclonal
antibodies. Malignancy was defined by metastases in nonchromaffin tissues.
RESULTS: There were higher stathmin expression levels in phaeochromocytomas compared to normal
adrenal tissue, by western blotting and reverse-transcriptase polymerase chain reaction, whereas immuno-
histochemical staining showed stathmin immunoreactivity in the cytoplasm of tumour cells. Malignant
neoplasms had significantly higher stathmin expression compared to benign neoplasms by western blotting
and immunohistochemical staining.
CONCLUSION: Malignant phaeochromocytomas and paragangliomas have significantly higher levels
of stathmin expression compared to benign tumours. The potential value of stathmin in predicting
malignancies requires further studies. [Asian J Surg 2011;34(1):15–22]
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Introduction
Phaeochromocytomas are rare tumours that arise in 
chromaffin cells of adrenal (medulla part) or paraga-
nglion tissues. Although usually benign, they can also
present as or develop into a malignancy.1–3 There are no
histological or biochemical markers for distinguishing
benign from malignant tumors,4–10 even though such 
a distinction is very important for clinical management,
especially because the diagnosis of malignancy requires
evidence of metastases to sites where chromaffin cells do
not exist.
Several studies utilizing RNA profiling have reported
various genes that are differentially expressed between
benign and malignant phaeochromocytomas and in
other endocrine tumours. Induction of stathmin phos-
phorylation after nerve growth factor treatment has been
found in PC12 cells.11,12 There have been two studies on
the expression of stathmin in phaeochromocytomas. The
study by Sadow et al4 has demonstrated higher stathmin
expression in phaeochromocytomas and paragangliomas
compared to normal adrenal tissues (medulla parts), as
well as stathmin expression in a wide variety of endocrine
tumours. The authors concluded that using stathmin as
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a potential biomarker of malignant phaeochromocytomas
requires further studies.4
In the other study, an expression microarray that con-
tained 7,770 cDNA clones was applied and the expression
profiles in 11 tumours were analysed and compared to
normal adrenal medulla.13 Stathmin (or STMN1, onco-
protein 18) was most conspicuously overexpressed among
the differentially expressed genes. Reverse-transcriptase
polymerase chain reaction (RT-PCR) analysis confirmed
mRNA overexpression in malignant tumours, and stathmin
protein overexpression was demonstrated by immunohis-
tochemistry (IHC) and western blot analysis. The authors
concluded that stathmin might be a possible diagnostic
marker for malignant phaeochromocytomas.9
Stathmin is a ubiquitous cytosolic protein that regu-
lates microtubule dynamics, and is associated with vari-
ous signalling pathways that influence cell growth and
differentiation. It acts as one of the key regulators in cell
division,14,15 and reportedly binds to tubulin dimers to
destabilize microtubules by preventing polymerization.16
The high level of expression in many types of cancer, includ-
ing leukaemia and lymphoma, and prostate, ovarian,
breast, hepatocellular, and oral squamous carcinomas,
has been reported.15,16
There are currently no reliable methods for predicting
the malignant potential of phaeochromocytomas and
paragangliomas,1,4,6–10,12,17–26 and the pathological dis-
tinction of benign and malignant phaeochromocytomas
remains a diagnostic challenge. Several studies have
attempted to distinguish the two using histopathological
classifications that incorporate retrospective assessment
of growth characteristics, cellularity, vascular invasion,
capsular invasion, mitotic figures, necrosis, and other
variables. However, no single pathological examination
can definitely distinguish between malignant and benign
phaeochromocytomas.1,4,6–10,12,17–26
The present study aimed to demonstrate clinicopatho-
logical parameters in malignant phaeochromocytoma,
and to investigate and compare the differential expres-
sions of stathmin in benign and malignant phaeochro-
mocytomas and paragangliomas.
Patients and methods
Formalin-fixed and paraffin-embedded specimens of
benign and malignant phaeochromocytomas and para-
gangliomas (n = 37) were analysed. Their clinical and
histopathological features were recorded. The tumours
comprised 24 benign phaeochromocytomas, 5 benign
paragangliomas, 5 malignant phaeochromocytomas, and
3 malignant paragangliomas. Benign diseases were diag-
nosed based on the absence of metastases at presentation
and during follow-up, whereas malignant disease was con-
firmed by the presence of metastases in nonchromaffin
tissue at presentation and during follow-up.
Western blotting
Proteins from frozen sections of normal adrenal tissue
(medulla part) (n = 1), phaeochromocytomas (n = 2), para-
ganglioma (n = 1), and malignant phaeochromocytoma
(n = 1) were extracted and separated by one-dimensional
sodium dodecyl sulphate polyacrylamide gel electrophore-
sis for 1 hour at 150 V. The proteins on the gels were then
transferred to polyvinylidene fluoride membranes and
subjected to immunoblot analysis with anti-stathmin anti-
body (ab11269, 1:1000 dilution; Abcam Inc., Cambridge,
MA, USA). Chemiluminescent substrate (Western Lightning;
PerkinElmer, Inc., Waltham, MA, USA) was evenly added
to detect reaction product. The membranes were exposed to
X-ray films and the results were analysed by the ECL sys-
tem (Amersham Biosciences, Piscataway, NJ, USA). Anti-
β-actin (Sigma Chemical, St. Louis, MO, USA) blotting at
a 1:1500 dilution was used to check for equal gel loading.
RT-PCR
The frozen specimens of benign phaeochromocytoma
and paired normal adrenal tissue (medulla part) from two
patients were collected and analysed by RT-PCR to de-
termine the mRNA levels of stathmin. Total RNA was
extracted using TRIzol Reagent from fresh specimens
obtained after surgery. S26 ribosomal protein mRNA, 
a housekeeping gene, was used as the internal control.
PCR was stopped at the exponential phase of amplifi-
cation for each gene: 32 cycles for stathmin and 25 for
S26. PCR was performed in an automatic DNA Thermal
Cycler 480 (Perkin–Elmer, Wellesley, MA, USA) and primers
for stathmin were Stathmin-F (5′-AAGGATTTTTCC-
CTGGAGGA-3′) and Stathmin-R (5′-TTTCTCCCCTT-
TAGCCCCTA-3′), whereas primers for S26 were S26-F
(5′-CCGTGCCTCCAAGATGACAAAG-3′) and S26-R (5′-
GTTCGGTCCTTGCGGGCTTCAC-3′). After PCR, 5 μL
reaction products were electrophoresed on 2% agarose gel.
The stathmin mRNA expression level was determined by
the ratio of signal intensity of stathmin to that of S26
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measured by 1D Image Analysis Software (Kodak Digital
Science, Rochester, NY, USA).
Immunohistochemical staining
Stathmin antibody (rabbit polyclonal antibody) was com-
mercially obtained (ab11269, 1:50 dilution; Abcam Inc.).
Stathmin immunostaining was performed on 5-μm sec-
tions of formalin-fixed, paraffin-embedded specimens
using the labelled strepatavidin–biotin method after
retrieving antigen and applying the chromogen diamino-
benzidine, as previously described.15 As a negative control,
duplicate sections were immunostained without exposure
to primary antibodies. Specimens from human hepatocel-
lular carcinoma and urothelial carcinoma were used as
positive controls.
To assess immunoreactivity quantitatively, the mean
percentage of positive staining tumour cells was deter-
mined by counting at least 10 random fields at 40× and
400× magnification in each section. The proportion of
tumour cells with positive staining was classified as < 50%
(scored as 1) and ≥ 50% (scored as 2). The intensity of the
stathmin staining was graded as no staining (0), weak stain-
ing (1+), moderate staining (2+), and strong staining (3+),
by evaluating the intensity of stain, as well as the distribu-
tion of staining in tumour cell cytoplasm. The intensity of
staining was determined by the strongest intensity present
among tumour cells. The stathmin IHC score was defined
as the multiplicity of staining intensity (0–3) and propor-
tion of positive staining (1 or 2). An experienced pathologist
blinded to the clinical data analysed the results.
Statistical analysis
Stathmin staining scores were averaged across duplicate
slides of all samples and across multiple tumour blocks.
Comparisons between groups were analysed by Wilcoxon
rank sum tests. All analyses were performed with the
Statistical Package for the Social Sciences software ver-
sion 11 (SPSS, Chicago, IL, USA). A p value of less than
0.05 was considered statistically significant.
Results
Western blotting
Western blotting showed a low level of stathmin expres-
sion in normal adrenal tissue (Figure 1). The size of the
band was detected as 18 kDa. There were stronger bands
for the two phaeochromocytomas and one paraganglioma.
The case of malignant phaeochromocytoma showed the
highest level of stathmin expression.
Stathmin mRNA levels in phaeochromocytoma and 
paired adrenal tissue
By RT-PCR, stathmin mRNA levels from the two patients
with benign phaeochromocytoma were significantly higher
than that of the paired adrenal gland tissue (medulla
part) (p < 0.05; Figure 2).
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Figure 1. Western blotting showed that the band of normal adrenal
tissue (medulla part) was more weakly positive compared to those
of benign phaeochromocytomas and paragangliomas. Malignant
phaeochromocytomas had the strongest expression level.
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Figure 2. (A) Quantitative level of stathmin mRNA (expressed as
%: stathmin/S26) in paired nontumoural adrenal tissue medulla
(medulla part; N) and benign phaeochromocytoma (T). There
was a significant difference in relative expression between non-
tumoural adrenal tissue (medulla part) and benign phaeochro-
mocytoma (p < 0.05). (B) Reverse transcription-polymerase chain
reaction in linear range of amplification showed stathmin mRNA
overexpression in benign phaeochromocytomas (T) compared
to paired nontumoural adrenal tissue (medulla part; N).
Clinical and histochemical staining
The clinical data of the 37 patients are listed in Table 1.
Five patients had malignant phaeochromocytoma, 24
patients had benign phaeochromocytoma, 3 patients 
had malignant paraganglioma, and 5 patients had benign
paraganglioma. The mean follow-up for each tumour 
was 9.5 years for benign phaeochromocytoma, 10.4 years
for benign paraganglioma, 9.6 years for malignant
phaeochromocytoma, and 11.3 years for malignant 
paraganglioma.
The clinicopathological characteristics of the five
malignant phaeochromocytoma and three malignant
paraganglioma patients are listed in Table 2. We analysed
some features that were considered to be associated with
increased incidence of malignant behaviour, such as tu-
mour necrosis, mitotic rate > 3/30 high-power fields, cap-
sular invasion, vascular invasion, lack of hyaline globules,
and high nuclear/cytoplasmic ratio. The Phaeochromo-
cytoma of Adrenal Gland Scaled Score of the eight malig-
nant phaeochromocytoma patients is listed in Table 1.7
Their total score was > 4. Malignant phaeochromocytomas
had a maximal diameter > 5 cm. The mean diameter of
malignant tumours is larger than that of benign tumours,
and maximal tumour diameter seems to be another indi-
cator of malignancy.
Stathmin was detected in all tumour types with vary-
ing levels of expression. Normal adrenal gland showed
negative to weak staining in the medulla and negative
staining in the cortex. Malignant phaeochromocytomas
had stronger immunoreactivity compared to benign tu-
mours (Figure 3). The IHC scores of stathmin immunore-
activity in the eight malignant tumours are shown in
Table 1, whereas comparison of stathmin IHC scores
between each tumour group is shown in Table 3. There
were statistically significant differences in stathmin IHC
scores between malignant phaeochromocytomas and
phaeochromocytomas (p = 0.01). There were also signifi-
cant differences in stathmin IHC score between malignant
paragangliomas and phaeochromocytomas (p = 0.05) and
between malignant phaeochromocytomas and paragan-
gliomas (p = 0.02). However, comparison of stathmin
immunoreactivity between benign and malignant para-
gangliomas revealed only borderline significance (p =
0.07). All three malignancy patients who died with disease
had strong stathmin immunoreactivity (IHC score = 6).
However, the correlations could not be analysed, because
of the very small patient number.
Discussion
Most phaeochromocytomas are benign and curable by
surgical resection, but some are clinically malignant,
which requires evidence of metastases to tissues where no
chromaffin cells exist. Currently, there is no effective cure
for malignant phaeochromocytoma,1,2 and no reliable
method for correctly predicting the malignant potential of
phaeochromocytomas and paragangliomas.1,4,6–10,12,17–26
In this series, there were some exceptions to each patho-
logical feature, and no single criterion was entirely reli-
able. Nonetheless, tumour size gave some hints, because
all the malignant tumours had a maximal diameter > 5 cm.
When the diameter of the tumour is > 5 cm, the possibil-
ity of malignancy should be kept in mind.
Combined and simultaneous use of different variables
can offer better diagnostic performance than a single vari-
able. Thompson has developed the Phaeochromocytoma
of the Adrenal Gland Scaled Score system based on a
series of pathological variables, including cellularity, vas-
cular invasion, capsular invasion, mitotic figures, necro-
sis, and other variables that predict prognosis of patients
with phaeochromocytomas.7 In the current study, all
eight patients with malignant disease had a total score 
of > 4 points, which provides diagnostic information in
predicting malignancies. However, the main problem 
in terms of clinical practice is the poor intra- and inter-
observer reproducibility.
Several molecular markers, such as the expression of
human telomerase reverse transcriptase, heat shock pro-
tein 90, Ki-67, secretogranin-II-derived peptide, and
numerous factors associated with angiogenesis reportedly
provide alternative methods for distinguishing malignant
from benign phaeochromocytoma.1,6,19,24 However, the
positive immunoreactivity rate is low, which lowers the
clinical application. Presently, there are still no markers
that can reliably distinguish between benign and malig-
nant phaeochromocytomas.
Stathmin has been shown to be overexpressed in many
malignancies. Its high expression level has been mentioned
in recent publications to serve as a biomarker in other
human cancers, such as urothelial carcinoma, metastatic
breast cancer, medulloblastoma, colorectal cancer, and
hepatoma.13–16 Stathmin upregulation has also been re-
ported in a number of epithelial neoplasms, and in highly
proliferating endocrine carcinomas. Compared to currently
available neuroendocrine markers, such as chromogranin,
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Table 1. Pathology data of patients with malignant phaeochromocytomas (n = 5) and malignant paragangliomas (n = 3)
Age Site of
Tumour 
Survival Nuclear Increased Hyaline 
Increased High Vascular/
PASS 
Stathmin 
(yr)
Sex Tumour type
metastasis
size 
status polymorphism cellularity globules
mitotic rate N/C Necrosis capsular IHC staining
score
IHC 
(cm) (>3/30HPF) ratio invasion score
1 45 M Lt adrenal Regional 5 × 5 × 4 AWD (+) (+) (+) (–) (–) (–) (+) S-100 (+) 6 4
LN Chromogranin (+),
Synaptophysin (+)
Vimentin (+)
2 38 F Lt adrenal Lung 15 × 11 × 9 AWD (+) (+) (–) (–) (+) (–) (+) S-100 (+) 6 4
Chromogranin (+),
Synaptophysin (+)
3 61 M Bil adrenal Regional 10 × 8 × 7 DWD (+) (–) (–) (–) (–) (–) (+) S-100 (+) 5 6
LN Chromogranin (+),
Synaptophysin (+)
4 33 M Rt adrenal Regional 5 × 4 × 3 DWD (+) (+) (–) (–) (+) (–) (–) S-100 (+) 6 6
LN Chromogranin (+),
Synaptophysin (+)
5 43 F Rt adrenal Regional 5 × 4 × 2.5 DWD (+) (+) (–) (+) (+) (–) (+) Chromogranin (+), 6 6
LN Synaptophysin (+)
6 14 F Paraganglioma Regional 5 × 5 × 3 AWD (+) (+) (–) (–) (–) (–) (+) S-100 (+) 6 6
LN Chromogranin (+),
Synaptophysin (+) 
Vimentin (+)
7 21 M Paraganglioma Liver 10 × 8 × 7 AWD (+) (+) (–) (+) (+) (–) (–) S-100 (+) 7 4
Chromogranin (+),
Synaptophysin (+)
8 21 M Paraganglioma Regional 7 × 5 × 6 AWD (–) (–) (–) (–) (–) (–) (–) S-100 (+) 5 4
LN Chromogranin (+), 
Synaptophysin (+)
N/C = nucleus to cytoplasm; IHC = immunohistochemistry; PASS = Phaeochromocytoma of the Adrenal gland Scaled Score; M = male; Lt = left; LN = lymph node; AWD = alive with disease;
F = female; Bil = bilateral; DWD = dead with disease.
synaptophysin and neuron-specific enolase, the utility 
of stathmin for diagnosis of malignant phaeochromo-
cytoma has yet to be confirmed.4 The current study
showed higher levels of stathmin expression in phaeochro-
mocytomas compared to normal adrenal tissue (medulla
part) by western blotting and RT-PCR. The results also
demonstrated significant differences in stathmin IHC
scores between malignant and benign tumours. Further-
more, the IHC scores of stathmin in the three patients
who died with disseminated malignant phaeochromocy-
tomas were higher than those in patients who survived.
Thus, correlations between stathmin expression levels
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Table 2. Clinical data of the study patients (n = 37)
Diagnosis
Cases Mean age at Sex ratio Mean maximum tumour Mean follow-up 
(n) diagnosis (yr) (SD) (F:M) diameter (cm) (yr)
Malignant phaeochromocytoma 5 44 (10.6) 0.67:1 8 9.6
Malignant paraganglioma 3 18.7 (4.0) 0.5:1 7.3 11.3
Phaeochromocytoma 24 44.7 (11.2) 0.85:1 4.8 9.5
Paraganglioma 5 39.6 (16.1) 1.5:1 4.5 10.4
F = female; M = male.
C
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Figure 3. (A) Primary malignant adrenal phaeochromocytoma with sustentacular cells and Zellballen pattern (patient 4 in Table 1)
(haematoxylin and eosin stain, 200× magnification) and immunohistochemical staining with antistathmin antibody (200× magnifi-
cation). (B) Benign phaeochromocytoma specimen [staining intensity (SI): 2+; percentage of positive staining (% staining): 40%]. 
(C) Malignant paraganglioma specimen (patient 6 in Table 1) (SI: 3+; % staining: 85%). (D) Malignant phaeochromocytoma speci-
men (patient 4 in Table 1) (SI: 3+; % staining: 60%).
and prognosis in malignant phaeochromocytomas deserve
further study.
This study had some limitations. First, the small num-
ber of cases with malignant tumours was a major problem
for statistical analysis. The number of specimens was far
too small to make any definitive conclusions. Second, the
number of patients with apparently benign primary
tumours who subsequently developed metastases could
not be predicted, despite the long mean follow-up period
of about 10 years (9.5 years in phaeochromocytomas and
10.4 years in paragangliomas).
In conclusion, significant differences of stathmin
expression between benign and malignant phaeochromo-
cytomas, as well as in paragangliomas, make stathmin 
a potential biomarker for diagnosing malignancies.
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